Smartwatches and video exams: a new way to predict MG Flare-Ups?
NCT ID NCT07787247
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This pilot study explores whether continuous monitoring with wearable devices and remote neurological exams can detect worsening in people with myasthenia gravis (MG), a condition causing fluctuating muscle weakness. The goal is to see if this technology is reliable and if patients can stick with it for 12 months. If it works, it might help catch flare-ups early and avoid hospital visits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Remote monitoring program using wearable devices (e.g., Fitbit) and telemedicine-based neurological exams
- What this could lead to
- If successful, this approach could enable earlier detection of MG worsening, potentially reducing hospitalizations and emergency treatments.
- What could go wrong
- This is a small pilot study focused on feasibility, not effectiveness. The technology may not reliably predict flare-ups, and patient compliance could be low.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 18 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Myasthenia Gravis Patients who satisfy the study's eligibility criteria
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subject 1. Has the capacity to understand and sign an informed consent form 2. ≥18 years old 3. Diagnosed with acquired autoimmune MG based on clinical syndrome and seropositivity for MG associated autoantibodies (AChR binding, MuSK, or LRP4 antibodies), and/or a decremental response on repetitive nerve stimulation, positive single fiber electromyography (EMG) or positive edrophonium test 4. Subject has been previously evaluated in a face-to-face clinical encounter at participating study site or referral site within the prior 3 years 5. Primary language is English, or equivalent level of English language fluency 6. Required disease severity range previously judged by the Investigator. MGFA class 1-4a within 3 years of diagnosis without other chronic medical conditions, which compromise participation. 7. Having MG-ADL score above 2 upon entrance to study 8. Patients considered by study PI not to require hospitalization at time of entrance 9. The patient has internet capability and a smart phone compatible with the apps required by the study. Exclusion Criteria: Disease Specific Exclusion Criteria 1. Inability to comply with study protocol for monitoring 2. Current MGFA Severity Class IVb or V, or patients in remission with MGFA Class 0 3. Any significant medical/psychiatric condition that, in the opinion of the Investigator, may interfere with interpretation of subject evaluation(s) or protocol compliance 4. Any disorder that could limit ability to assess myasthenia gravis specific deficits (not including planned or recent thymectomy) 5. Pregnancy, based on the evaluator's judgment, if the subject is deemed not safe to undergo evaluation or comply with study visit requirements. 6. Lack of effective internet connection or ability to use study telemedicine station and monitors 7. Home environment prevents use of study equipment 8. Likelihood of leaving DC, Maryland, or Virginia area in year after initiation of study 9. Subject is already participating in a research study -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Myasthenia gravis (MG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The George Washington University
RECRUITINGWashington D.C., District of Columbia, 20037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
- Engineered immune cells take aim at autoimmune diseases
- New drug aims to ease daily struggles of myasthenia gravis
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
- New study aims to uncover hidden clues in myasthenia gravis